Understanding the Modified Glasgow Prognostic Score
The recent meta-analysis published in Medicine delves into the prognostic value of the modified Glasgow Prognostic Score (mGPS) in patients with small cell lung cancer (SCLC). This study is pivotal as it sheds light on the potential of mGPS as a reliable indicator for patient prognosis in a field where predictive accuracy is crucial for treatment strategies.
The Source Article Details
Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis by Yulian Xie et al. in 2023.
The Source Article's Abstract
The prognostic role of pretreatment modified Glasgow Prognostic Score (mGPS) in small cell lung cancer (SCLC) patients remains unclear now.
The PubMed, EMBASE, Web of Science, and CNKI electronic databases were searched up to December 14, 2022. The primary and secondary outcomes were overall survival and progression-free survival, respectively. The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to assess the association between pretreatment mGPS and survival of SCLC patients. Subgroup analysis based on the country, tumor stage, treatment and comparison of mGPS were further conducted and all statistical analyses were performed by STATA 15.0 software.
A total of ten retrospective studies involving 2831 SCLC patients were included. The pooled results demonstrated that elevated pretreatment mGPS was significantly related to poorer overall survival (HR = 1.90, 95% CI: 1.36-2.63, P < .001) and progression-free survival (HR = 1.40, 95% CI: 1.13-1.74, P = .002). Subgroup analysis stratified by the country, tumor stage, treatment and comparison of mGPS also showed similar results.
Pretreatment mGPS was significantly associated with prognosis in SCLC and patients with elevated mGPS experienced obviously worse survival. Thus, pretreatment mGPS could serve as a novel and reliable prognostic indicator in SCLC patients.
The Source Article References
- What’s new in SCLC? A review. by Oronsky, 2017 in Neoplasia (New York, NY)
- The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. by Nicholson, 2016 in J Thor Oncol
- Using inflammatory indexes and clinical parameters to predict radiation esophagitis in patients with small-cell lung cancer undergoing chemoradiotherapy. by Qiu, 2022 in Front Oncol
- Value of plasma vitamin D level and nomogram model for predicting the prognosis of patients with small cell lung cancer treated with platinum plus etoposide as first-line chemotherapy. by Zhang, 2022 in Am J Trans Res
- Cancer statistics, 2021. by Siegel, 2021 in CA Cancer J Clin
- Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. by Belluomini, 2022 in Semin Oncol
- Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis. by Chen, 2022 in Eur Rev Med Pharmacol Sci
- Moving immune checkpoint inhibitors to early non-small cell lung cancer: a narrative review. by Viscardi, 2022 in Cancers
- Chronic hyperglycemia is an adverse prognostic factor for locoregional recurrence-free survival in small cell lung cancer patients treated with radical radiotherapy. by Kong, 2022 in Thorac Cancer
- Comprehensive next-generation sequencing reveals novel predictive biomarkers of recurrence and thoracic toxicity risks after chemoradiation therapy in limited stage small cell lung cancer. by Li, 2022 in Int J Radiat Oncol Biol Phys
- Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study. by Wang, 2022 in J Thorac Dis
- Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer. by Sun, 2022 in BMC Cancer
- Pretreatment albumin/globulin ratio predicts the prognosis for small-cell lung cancer. by Zhou, 2016 in Medicine (Baltim)
- Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). by Mirili, 2019 in Int J Clin Oncol
- Inflammation-based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy. by Chen, 2022 in J Clin Lab Anal
- Prognostic value of pretreatment d-dimer level in small-cell lung cancer: a meta-analysis. by Li, 2021 in Technol Cancer Res Treatment
- The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis. by Wang, 2020 in Nutr Cancer
- A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis. by Nie, 2020 in Arch Gynecol Obstet
- A meta-analysis of Glasgow prognostic score and modified Glasgow prognostic score as biomarkers for predicting survival outcome in renal cell carcinoma. by Tong, 2020 in Front Oncol
- Prognostic and clinical significance of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients. by Wu, 2021 in Aging (Milano)
Citing the Source Article (APA)
Xie, Y., Li, H., Hu, Y. (2023). Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis. Medicine (Baltimore), 102(45), e35962-e35962. 10.1097/MD.0000000000035962
Methodology and Key Findings
The research involved a comprehensive review of ten retrospective studies, encompassing a total of 2831 SCLC patients. The primary focus was on overall survival and progression-free survival, with the findings indicating a significant correlation between elevated mGPS and poorer survival outcomes.
- Overall survival was notably affected with a hazard ratio (HR) of 1.90.
- Progression-free survival also showed a similar trend with an HR of 1.40.
Implications for Clinical Practice
The study’s outcomes suggest that mGPS could be a novel and reliable prognostic indicator in SCLC patients. This could lead to more tailored treatment approaches, potentially improving patient outcomes in this aggressive cancer type.
Furthermore, the study highlights the need for more personalized care strategies in oncology, particularly in lung cancer treatment, where prognosis and treatment response vary widely among patients.
Given the nature of this article as a systematic review and meta-analysis, let’s evaluate it using the PP-ICONS approach:
- Problem: Assessing the prognostic value of mGPS in SCLC.
- Patient: 2831 patients with small cell lung cancer.
- Intervention: Analysis of pretreatment mGPS.
- Comparison: Different levels of mGPS and their impact on survival.
- Outcome: Overall and progression-free survival.
- Number of Subjects: A total of 2831 SCLC patients across ten studies.
- Statistics: Hazard ratios (HRs) and 95% confidence intervals (CIs) used to assess survival association.
What are your thoughts on the potential of mGPS in improving the prognosis of SCLC patients? Share your insights and join the discussion below.